MedTech Atlas
Back to medical device regulatory guideAll countries
Asia PacificENPublic regulatory overview

Indonesia

Country Overview Market Notes: Indonesia operates a strong distributorled market structure for foreign manufacturers. Fluency in Bahasa Indonesia regulatory requirements and the ab...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingSupportive evidence

NMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Indonesia
  • Product line: Medical devices
  • Regulator / source: Market Notes: Indonesia operates a strong distributor-led market structure for foreign manufacturers. Fluency in Bahasa Indonesia regulatory requirements and the ability to execute locally through a qualified distributor are essential for successful market entry.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
  • Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
  • Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Country Overview

  • Market Notes: Indonesia operates a strong distributor-led market structure for foreign manufacturers. Fluency in Bahasa Indonesia regulatory requirements and the ability to execute locally through a qualified distributor are essential for successful market entry.

Regulatory Authority

  • Primary Authority: Ministry of Health (Kementerian Kesehatan) medical device regulatory units
  • Submission Portal: Regalkes, the online registration system for medical devices and PKRT products

Device Classification System

Local Class Risk Level Approximate EU Equivalent Notes
A Low Class I Basic, low-risk devices
B Low-Moderate Class IIa General medical devices
C Moderate-High Class IIb Higher-risk devices requiring more extensive documentation
D High Class III Highest risk; most stringent review requirements

Official Sources and Verification Date

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.